JPM 2026 was touted as the event that would usher in the best year in biotech in a long time. But when it happened there was a distinct lack of mega-deals to shout about. The elephant, you might say, was not in the room. Does this bode ill for 2026? Or is news of such […]
How can companies with promising science secure the capital they need to develop drugs What does pharma need to fill their pipelines as they look to negotiate looming patent cliffs London, UK, 7 October 2025: Optimum Strategic Communications (Optimum), the specialist life sciences communications consultancy, will be hosting its 17th Annual Healthcare Investor Conference on Thursday 9 October […]
How can companies with promising science secure the capital they need to develop drugs What does pharma need to fill their pipelines as they look to negotiate looming patent cliffs London, UK, 7 October 2025: Optimum Strategic Communications (Optimum), the specialist life sciences communications consultancy, will be hosting its 17th Annual Healthcare Investor Conference on Thursday […]
The Board of Directors of Calliditas Therapeutics AB (publ) unanimously recommends that the shareholders and holders of American Depositary Shares (“ADS”) of Calliditas Therapeutics AB (publ) (jointly the “Securityholders”) accept the public tender offer by Asahi Kasei Corporation. Background This statement is made by the Board of Directors (the “Board”) of Calliditas Therapeutics AB (publ) […]
Paratek’s successful commercialisation platform to advance novel therapies developed organically and through acquisitions Paratek adds ‘final-mile’ capabilities to AMR efforts COPENHAGEN, September 21, 2023 – With the closing of the acquisition of Paratek Pharmaceuticals, Inc. (“Paratek”), a commercial-stage biopharmaceutical company focused on the development and commercialisation of novel therapies for life-threatening diseases and other public health […]
